SEARCH

SEARCH BY CITATION

References

  • 1
    Hammer J, Abell T, Cutts T, Talley NJ. Epidemiology of disordered gastrointestinal function and impact of chronic gastrointestinal symptoms on quality of life in diabetes mellitus. In: HorowitzM, SamsonM, eds. Diabetes Mellitus. ???: John Wiley and Sons, 2004: 121.
  • 2
    Luo J, Abell TL, Nash K, Cutts T. Gastric electrical stimulation is associated with reduced health care costs, compared with baseline costs and medical controls. Gastroenterology 1999; 116: A77.
  • 3
    Tseng M, Sadler D, Wong J et al.Radiologic placement of central venous catheters: rates of success and immediate complications in 3412 cases. Can Assoc Radiol J 2001; 52: 37984.
  • 4
    Kock HJ, Pietsch M, Krause U, Wilke H, Eigler FW. Implantable vascular access systems: Experience in 1500 patients with totally implanted central venous port systems. World J Surg 1998; 22: 126.
  • 5
    Docktor BL, Sadler DJ, Gray RR, Saliken JC, So CB. Radiologic placement of tunneled central catheters: rates of success and immediate complications in a large series. Am J Roentgenol 1999; 173: 45760.
  • 6
    Prakash A, Wagstaff AJ. Domperidone: a review of its use in diabetic gastropathy. Drugs 1998; 56: 42945.
  • 7
    Luo J, Rashed H, Eaton P, Voeller G, Familoni J, Abell T. Long term treatment of gastric electrical stimulation is associated with autonomic nervous system changes. Gastroenterology 2001; 118: A1187.
  • 8
    Rashed H, Luo J, Cutts T, Abell TL. Practitioner-rated score (ADAPS) correlates with symptom severity in-patients with severe dyspepsia treated with long-term device, prokinetics and behavioral treatment. Neurogastroenterol Motil 2000, 12: 492.
  • 9
    Cutts TF, Abell TL, Luo J, Eaton P, Kores R. Practitioner-rated diagnostic and predictive score (ADAPS) correlates with quality of life improvement in gastroparesis patients undergoing gastric electrical stimulation. Gastroenterology 1999, 116: A53.
  • 10
    Ebell MH, Warbasse L, Brenner C. Evaluation of the dyspeptic patient: a cost-utility study. J Fam Pract 1997; 44: 54555.
  • 11
    Delaney BC, Wilson S, Roalfe A et al. Cost effectiveness of initial endoscopy for dyspepsia in patients‘ ages 50 years: a randomized controlled trial in primary care. Lancet 2000; 3569: 19659.
  • 12
    O'Connor JB, Provencale D, Brazer S. Economic considerations in the treatment of gastroesophageal disease: a review. Am J Gastroenterol 2000; 951: 335664.
    Direct Link:
  • 13
    Buttafuoco A, Keighley MR. Cost of pelvic floor repair for fecal incontinence. Dig Surg 2000; 17: 6236.
  • 14
    Feagan BG. Review article: economic issues in Crohn's disease-assessing the effects of new treatments on health-related quality of life. Aliment Pharmacol Ther 1999; 13 (Suppl 4): 2938.
  • 15
    Groeneveld PW, Lieu TA, Fendrick AM et al. Quality of life measurement clarifies the cost-effectiveness of Heliobacter pylori eradication in peptic ulcer disease and uninvestigated dyspepsia. Am J Gastroenterol 2001; 96: 33847.
  • 16
    Creed F, Ratcliffe J, Fernandez L et al. Health-related quality of life and health care costs in severe, refractory irritable bowel syndrome. Ann Intern Med 2001; 134: 8608.
  • 17
    Miller AR, Cantor SB, Peoples GE, Pearlstone DB, Skibber JM. Quality of life and cost effectiveness analysis of therapy for local and recurrent rectal cancer. Dis Colon Rectum 2000; 43: 1695703.
  • 18
    Hahn NA, Yan S, Strassels S. Impact of irritable bowel syndrome on quality of life and resource use in the United States and United Kingdom. Digestion 1999; 60: 7781.
  • 19
    Abell TL, Camilleri M, Hench VS, Malagelada JR. Gastric electromechanical function and gastric emptying in diabetic gastroparesis. Eur J Gastroenterol Hepatol 1991; 3: 1637.
  • 20
    Talley NJ, Weaver AL, Zinmeister AR. Impact of functional dyspepsia on quality of life. Dig Dis Sci 1995; 40: 5849.
  • 21
    Soykan I, Sivri B, Sarosiek I, Kiernan B, McCallum RW. Demography, clinical characteristics, psychological and abuse profiles, treatment and long-term follow-up of patients with gastroparesis. Dig Dis Sci 1998; 43: 2398404.
  • 22
    Bell RA, Jones-Vessey K, Summerson JH. Hospitalizations and outcomes for diabetic gastroparesis in North Carolina. South Med J 2002; 95: 12979.
  • 23
    Martin BC, Ganguly R, Pannicker S, Frech F, Barghout V. Utilization patterns and net direct medical cost to Medicaid of Irritable bowel syndrome. Curr Med Res Opin 2003; 19: 77180.
  • 24
    Cutts TF, Abell TL, Karas JG, Kuns J. Symptom improvement from prokinetic therapy corresponds to improved quality of life in patients with severe dyspepsia. Dig Dis Sci 1996; 41: 136978.
  • 25
    Rockwood TH, Church JM, Fleshman JW et al. Patient and surgeon ranking of the severity of symptoms associated with fecal incontinence. Dis Colon Rectum 1999; 42: 152532.
  • 26
    Sloan JA, Aaronson N, Cappelleri JC, Fairclough DL, Varricchio C and Clinical Significance Consensus Meeting Group Assessing the clinical significance of single items relative to summated scores. Mayo Clin Proc 2002; 77: 47087.
  • 27
    Cella D, Bullinger M, Scott C, Barofsky I. and The Clinical Significance Consensus Meeting Group Group vs. individual approaches to understanding the clinical significance of differences or changes in quality of life. Mayo Clin Proc 2002; 77: 38492.